SCHEDULE 13D
SCHEDULE 13DSchedule 13D ownership disclosure
NOVABRIDGE BIOSCIENCES
Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) · CUSIP: 44975P103
Event date: 2025-01-29
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- CBC Investment I-Mab LimitedReported CIK 0001845246
Shares: 11,784,164.00 · Class: 6.3%
- IBC Investment Seven Limited
Shares: 3,641,554.00 · Class: 1.9%
- CBC SPVII LIMITED
Shares: 5,574,560.00 · Class: 3.0%
- C-Bridge II Investment Ten Limited
Shares: 2,369,546.00 · Class: 1.3%
- Everest Medicines Limited
Shares: 6,078,571.00 · Class: 3.2%
- Nova Aqua Limited
Shares: 4,122,768.00 · Class: 2.2%
- C-Bridge Healthcare Fund II, L.P.
Shares: 14,153,710.00 · Class: 7.6%
- C-Bridge Healthcare Fund GP II, L.P.
Shares: 14,153,710.00 · Class: 7.6%
- C-Bridge Capital GP, Ltd.
Shares: 23,369,824.00 · Class: 12.5%
- I-Bridge Healthcare Fund, L.P.
Shares: 9,216,114.00 · Class: 4.9%
- I-Bridge Healthcare GP, L.P.
Shares: 9,216,114.00 · Class: 4.9%
- I-Bridge Capital GP, Ltd.
Shares: 9,216,114.00 · Class: 4.9%
- Wei Fu
Shares: 33,571,163.00 · Class: 17.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-003167
- Form type
- SCHEDULE 13D
- Filer
- CBC Investment I-Mab Ltd
- CIK
- CIK 1845246
- Filed
- Feb 05, 2025
- Reporting period
- Jan 29, 2025
- Description
- Schedule 13D beneficial ownership